An item in the April 25, 2001, issue of BioWorld Today should have said BioMarin Pharmaceutical Inc., of Novato, Calif., has Aldurazyme in a Phase III pivotal trial and, pending positive data, plans to file its biologics license application in the U.S. by the end of the year, with approval sought in Europe shortly thereafter.

Editor¿s Note: The correction will be made in BioWorld Online.

No Comments